This interpretation is in keeping with the results of a 2017 study by Yamaguchi et al., which showed that expression of ERα, FOXA1, and TFF1 were all significantly reduced in an MCF7-derived tamoxifen-resistant breast cancer cell line, and that the canonical and non-canonical NFκB signaling pathways were significantly upregulated47. This evidence concerns the gene FOXA1 and breast carcinoma.